Murray P K, Eaton B T
CSIRO Australian Animal Health Laboratory, Geelong, Victoria.
Aust Vet J. 1996 Jun;73(6):207-10. doi: 10.1111/j.1751-0813.1996.tb10036.x.
Isolation of 8 serotypes of bluetongue virus (BTV) in Australia has led to widespread debate on how to prepare for an outbreak of bluetongue disease and the type of vaccine best suited to control bluetongue in Australia. This article describes the vaccine options under consideration by research workers and animal health administrators. The most widely discussed options are live attenuated virus, killed virus and virus-like particles (VLP) generated by recombinant baculoviruses. Attenuated virus vaccines are cheap and easy to produce and are administered in a single dose. They replicate in sheep without causing significant clinical effects and provide protection against challenge with virulent virus of the same serotype. The possibility that insects could acquire vaccine virus by feeding on vaccinated animals and transmit it to sheep or cattle cannot be eliminated. This poses a risk because attenuated viruses are teratogenic if ewes are infected in the first half of pregnancy. In addition, vaccine virus replication in insects and ruminants may lead to a reversion to virulence. Killed virus vaccines have been shown to be efficacious in small laboratory trials and cannot be transmitted to other animals in the field, but are significantly more expensive to produce than attenuated viruses and require at least 2 doses with adjuvant to elicit an immune response. More work is needed to properly assess their effectiveness and determine their cost of production. Recombinant VLP contain the 4 major structural proteins of BTV but no nucleic acid. VLP are relatively easy to isolate, but it is unlikely that the purification methods currently used in laboratories will be adapted for use commercially. Despite the enthusiasm of recent years, little commercial progress appears to have been made. Although scientific research in Australia and overseas has provided a number of options for development of bluetongue vaccines, the decisions on which to use in an outbreak are complex and will require, not only consideration of factors discussed here, but also agreement from industry and government.
在澳大利亚分离出8种血清型的蓝舌病病毒(BTV),引发了关于如何为蓝舌病疫情做准备以及最适合在澳大利亚控制蓝舌病的疫苗类型的广泛讨论。本文介绍了研究人员和动物卫生管理人员正在考虑的疫苗选择。讨论最为广泛的选择是减毒活病毒、灭活病毒以及由重组杆状病毒产生的病毒样颗粒(VLP)。减毒活病毒疫苗价格低廉且易于生产,只需单剂量接种。它们能在绵羊体内复制而不产生明显的临床症状,并能抵御相同血清型强毒病毒的攻击。无法排除昆虫通过吸食接种疫苗的动物而获得疫苗病毒并将其传播给绵羊或牛的可能性。这带来了风险,因为如果母羊在怀孕前半期感染,减毒病毒具有致畸性。此外,疫苗病毒在昆虫和反刍动物体内的复制可能导致毒力回复。灭活病毒疫苗在小型实验室试验中已显示出有效性,且不会在野外传播给其他动物,但生产成本比减毒病毒高得多,并且至少需要2剂加佐剂才能引发免疫反应。需要开展更多工作来正确评估其有效性并确定生产成本。重组VLP包含BTV的4种主要结构蛋白,但不含核酸。VLP相对容易分离,但目前实验室使用的纯化方法不太可能适用于商业用途。尽管近年来热情高涨,但商业进展似乎甚微。尽管澳大利亚和海外的科学研究为蓝舌病疫苗的开发提供了多种选择,但在疫情爆发时使用哪种疫苗的决策很复杂,不仅需要考虑本文讨论的因素,还需要行业和政府达成一致。